News | June 24, 2024
EMA approves Biocon Biologics’ new mAbs facility in India
Renews GMP certifications for India and Malaysia sites
Renews GMP certifications for India and Malaysia sites
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Subscribe To Our Newsletter & Stay Updated
